TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: rate of culture-confirmed clearance of the infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Pain of subsequent local infiltration of lidocaine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cessation of oropharyngeal cytomegalovirus excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: cessation of urinary cytomegalovirus excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: negative cultures of repeat esophageal specimens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Intent to undergo prostate cancer screening
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean scores of the Manchester Scar Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: breast cancer knowledge
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Time to discontinuation of treatment for any cause
Endpoint domain: Adverse events/effects
Primary endpoint: Weight gain and metabolic effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Delivery rates
Endpoint domain: Mortality/survival
Primary endpoint: surgical training efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: 6-Minute Walk Test (6-MWT) results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cross-sectional area of the musculus rectus femoris
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: St. George's Respiratory Questionnaire (SGRQ) score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: IL-6 levels after declamping
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: IL-10 levels after infusion of protamine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: CRP levels at 24th hour after CPB
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Plasma HIV-1 RNA levels <50 copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Social contacts
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Risk of early-onset heart failure (HF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Risk of late-onset heart failure (HF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Total gemigliptin plasma exposure (AUC(0‐∞))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Metabolic ratio of gemigliptin to LC15‐0636
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: drift rate (v)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: student scores on intervention items
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total number of incontinence episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Linking into the follow-up survey
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Roland and Morris disability questionnaire score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Accelerating the wound healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: exercise-induced skeletal muscle damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: post/pre-exercise CK ratios
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: serum sodium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: osmolality
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in proximal femur BMD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Beck scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean BDI scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of symptomatic muscle cramps
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in regional left ventricular function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Wall motion score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Frequency of sizable MCE no reflow phenomenon
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: AMS severity (AMS-C score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PM2.5 concentrations indoors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Air quality outcomes
Primary endpoint: PM2.5 concentrations outdoors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Air quality outcomes
Primary endpoint: PM2.5 concentrations in patios
Endpoint domain: Physiological/clinical
Endpoint subdomain: Air quality outcomes
Primary endpoint: LBP values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: hunger AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: desire to eat AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Eating frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of small bowel polyps
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Reduction in echocardiographic left anterior descending regional wall motion score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: No additional ST segment deviation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Balance measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SBM frequency rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: subjective IKDC score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Plasma guanidinoacetate levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma tHcys levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HRQoL improvement rates
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Median time-to-worsening FACT-L score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of medical referrals
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: VAS and VS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ketorolac requirement
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Urinary retention
Endpoint domain: Adverse events/effects
Primary endpoint: Recovery agitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: recurrent/persistent neurosensory detachment
Endpoint domain: Adverse events/effects
Primary endpoint: whole body accumulation of lactate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Genistein and total daidzein concentrations in breast tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Drug toxicity scores reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUASI score reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mitochondrial respiratory capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mitochondrial substrate sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decreased global circumferential strain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Strain rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Anterior regional strain rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Management of uncertainties related to survivorship
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 4-year estimated overall survival rate
Endpoint domain: Mortality/survival
Primary endpoint: asthma symptoms improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: reductions in albuterol use
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Volumes of gas insufflated per minute
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self-reported depression levels
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Improvement in communication
Endpoint domain: Life impact
Endpoint subdomain: Communication
Primary endpoint: Serum levonorgestrel levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bleeding irregularities
Endpoint domain: Adverse events/effects
Primary endpoint: total subjective cure rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proportion of patients who received a second surgery for UI
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: C(2.5) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to first patient-controlled analgesia use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total 24 h morphine requirements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevention of infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: sDFR achievement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: SADQH21 score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: home help costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: HIV infection risk
Endpoint domain: Mortality/survival
Primary endpoint: Surgical grade score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Extracellular fluid volume (ECFV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lowering of LDL-C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lipid outcomes
Primary endpoint: Total BMD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Cortical area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Cortical thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Cortical porosity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Seizure frequency/severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Root-mean-square of total ocular higher order aberrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ocular spherical aberration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HOMA-beta improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Adiponectin concentration increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Decrease in IL-18
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Total burden of myocardial infarction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Occurrence of reperfusion arrhythmia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mortality after pulmonary embolism
Endpoint domain: Mortality/survival
Primary endpoint: severe late RT-related toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: median time to severe late RT-related toxicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of autoantibodies during follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Activated Partial Thromboplastin Time (APTT) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Efficacy on inflammatory lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy on noninflammatory lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse effects (stinging, erythema, desquamation)
Endpoint domain: Adverse events/effects
Primary endpoint: R0 resection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Cortical thickness in the left supramarginal gyrus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: mean number of packed RBC units transfused
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Total score of symptoms and signs
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Blood pressure changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Loss of 2 or more lines of best corrected visual acuity (BCVA)
Endpoint domain: Adverse events/effects
Primary endpoint: Mean subjective refraction within 1 D of emmetropia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of abuse-related opioid effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Triggers of withdrawal symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Persistence with ICBT
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Perceived ease of parent-adolescent sexual communication
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: mean daily minutes of MVPA in care
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of time spent in MVPA in care per day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: left leg stance time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Information relayed
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Antidepressant use at baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lens wearing comfort
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: lens moisture maintenance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recruitment of older patients
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: walk distance on the 6-min walk test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean ambulatory diastolic blood pressure (DBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean ambulatory systolic blood pressure (SBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rates of PVS among PCPs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of diagnosis of S/A by eye specialists
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall survival at 69 months
Endpoint domain: Mortality/survival
Primary endpoint: Cerebral oxygen uptake rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Extrapyramidal symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: neurophysiological impairment of the median nerve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: patient-oriented findings
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Pain during needle piercing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain during probe insertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Leukocyte and eosinophil counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Diarrhea frequency
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of sedation-related and procedural-related complications
Endpoint domain: Adverse events/effects
Primary endpoint: IVUS lumen volumes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: neointimal volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Mean salivary cortisol concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: ASL perfusion in cortex
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: ASL perfusion in whole kidney
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: T1 longitudinal relaxation time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Depth of anaesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of hypoglycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage in target range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: drainage volume collected after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: headache response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement in pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean aqueous humor levels of ofloxacin and ciprofloxacin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: help-seeking intention
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Two-year survival without neurological impairment
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of infants free of neurological impairment
Endpoint domain: Mortality/survival
Primary endpoint: Drug-related grade 3-4 adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: HDL function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in bacterial overgrowth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Bone resection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Contrast Sensitivity (CS) values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse perinatal outcome
Endpoint domain: Mortality/survival
Primary endpoint: Small-for-gestational-age infants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of intervention for abnormal test result
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: self-reported improvements in physical well-being
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: self-reported improvements in psychological well-being
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: triglyceridemia reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction in wave reflections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Tumor blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: General effective rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: AUC0‐( (microg x h/ml)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C(max) (microg/ml)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C(min) (microg/ml)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hemoglobin A1C decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Hypoglycemia rates
Endpoint domain: Adverse events/effects
Primary endpoint: Quality of Communication (QOC) score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Length of stay in the ICU
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: BMI value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: (129) Xe VDP improvement post-salbutamol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: (3) He VDP improvement post-salbutamol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: (129) Xe MRI COV change pre- and post-salbutamol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes